ORAL PRESENTATIONS

Friday, 4th October
14.15 h – 15.15h

EFFECTS OF SMOKING EXPOSURE ON SMOKING RELAPSE
Maxine L. Stitzer, Ph.D. and Laura M. Juliano, Ph.D.
Johns Hopkins University School of Medicine, Baltimore, USA

GENERAL PRACTITIONERS’ VIEWS ON THE PROVISION OF NICOTINE REPLACEMENT THERAPY AND BUPROPION
Andy McEwen MSc, BA and Robert West PhD, BSc
St. George’s Hospital Medical School, London, U.K.

PATTERNS OF EARLY SMOKING ONSET
Elizabeth McMillan-Davey MEd, Jennifer O’Loughlin PhD, Jill Tarasuk MSc, Garbis Meshefedjian MSc and Joseph DiFranza MD
Direction de santé publique de Montréal-Centre, Montreal, Canada

CHARACTERISATION OF GENETIC VARIATION IN THE HUMAN DOPAMINE TRANSPORTER GENE AND ITS RELEVANCE TO SMOKING BEHAVIOUR
Elaine Johnstone PhD, Louisa Draper, Emma York BA, Robyn Jacob BSc, Siân Griffiths BSc, Mike Murphy MSc and Robert Walton MD
Cancer Research UK General Practice Research Group, Oxford, UK

CESSATION RATES IN A PLACEBO-CONTROLLED TRIAL OF NICOTINE GUM FOR SMOKING REDUCTION
Poul Wennike MD, Tobias Danielsson BSc, Björn Landfeldt MA, Ake Westin MSc and Philip Tønnesen MD
Dept. of Pulm. Medicine, Gentofte University Hospital, Copenhagen, Denmark
Pharmacia AB, Consumer Healthcare, Helsingborg, Sweden

A RE-ASSESSMENT OF CYP2A6 AND RISK FOR SMOKING
R.F. Tyndale PhD, E. Hoffmann MSc, B. Xu MD, C. Xu MD PhD, Y.S. Rao MSc, S. Goodz MSc and E.M. Sellers MD PhD
CAMH and Department of Pharmacology, University of Toronto, Toronto, Canada

POSTER PRESENTATIONS

Friday, 4th October
12.30 h – 14.00h

A1 INTERVENTION

CREATING AND SUSTAINING A COMPREHENSIVE TOBACCO RELATED RESEARCH PROGRAM AT THE STATE LEVEL
Francisco O. Buchting PhD, MF Bowen PhD and Susanne Hidlebrand-Zanki PhD
University of California, Oakland, U.S.A.

USE OF VIRGINIA TOBACCO SETTLEMENT FUNDS TO SUPPORT RESEARCH ON CAUSES OF YOUTH SMOKING
Roy W. Pickens PhD, Robert L. Balster PhD and Margaret E. White
Virginia Commonwealth University, Richmond, VA, U.S.A.

FINANCIAL INCENTIVES FOR IMPROVING SMOKING CESSATION AT COMMUNITY LEVEL: A PILOT PROJECT IN CATALONIA, SPAIN
Helios Pardell, Esteve Saltó, Mireia Jané, Ricard Tresserras, Josep Ll. Taberner, Mª Teresa Faixedas, Moisés Costa and Lluis Salleras
Department of Health and Social Security. Autonomous Government of Catalonia, Barcelona, Spain

GALICIAN NETWORK SMOKE-FREE HOSPITALS (1996-2001)
Begoña Alonso, Socorro Fernández and Jorge Suanzes
Department of Public Health. Regional Government of Galicia (Spain)

SMOKE FREE AREA AT THE UNIVERSITAT DE LES ILLES BALEARS
M. Lluc Bauzá RN, Jordi Pericàs PhD and Esperança Ponsell BSc
Universitat de les Illes Balears, Spain

HEALTH EDUCATION AS A TOOL FOR RISK PREVENTION. A SCHOOL PROGRAMME ON TOBACCO: BEYOND TRANSVERSALITY
José María Fuentes-Pila and F. Javier Ayesta
Fac. Medicine, Univ. Cantabria, Santander, Spain

EVALUATION OF A WORKSITE SMOKING CESSATION PROGRAM
Padraic J Ryan MRCGP FFOM, Nicola JD Forster Msc and Deborah Holder BSc
GlaxoSmithKline, United Kingdom

SMOKING CESSATION PROGRAM IN BARCELONA’S COMMUNITY PHARMACY
Mireia Massot Mesquida, Anna Mª Fornés Tolrà and Mercè Sellés Valls
Community Parmacist, Barcelona, Spain

A COMPREHENSIVE TOBACCO TREATMENT PROGRAMME ATTENDED FROM A PHARMACY
Gloria Gago, José María Fuentes-Pila and F. Javier Ayesta
Fac. Medicine, Univ. Cantabria, Santander, Spain

TOBACCO ADDICTION TREATMENT IN DIGITAL SOCIETY
Antonio García Baena and Francesc Abella Pons
Hospital de Santa Maria, Lleida, Spain

CESSATION FOR INDIGENOUS PEOPLE: NATIONAL QUIT CAMPAIGN AND QUITLINE SERVICE IN NEW ZEALAND
Trish Young MSS
The Quit Group, Wellington, New Zealand

EFFECTIVENESS OF TELEPHONE COUNSELING FOR SMOKING CESSATION
Edward Lichtenstein Ph.D.
Oregon Research Institute, Eugene, U.S.A.

TELEPHONE HELPLINES: ARE THEY A USEFUL PUBLIC HEALTH INTERVENTION FOR SMOKING CESSATION?
Hazel M. Gilbert PhD and Stephen Sutton PhD
Health Behaviour Unit, University College London, London, UK

WHO CALLS THE QUITLINE? THE CHARACTERISTICS OF SMOKERS SEEKING ADVICE VIA TELEPHONE HELPLINES
Hazel M. Gilbert PhD and Stephen Sutton PhD
Health Behaviour Unit, University College London, London, UK

INTEGRATING SPIRITUALITY IN TELEPHONIC TOBACCO CESSATION COUNSELING
Elizabeth E. Fildes EdD, Richard Bissett PhD, Susie Skarl MLS, Richard Hatch MD, George Kaiser MD, Telisa Clevenger-Smith MSOD, Mandy Canales-Salazar BS, Lori Kozlowski BA and John Spilotro
Nevada Tobacco Users’ Helpline, Las Vegas, USA

SPIRITUAL PRACTICES AND BELIEFS: RESOURCES FOR SMOKING CESSATION?
David Gonzales PhD, Heather Murphy BA, Donovan Redtomahawk, Elizabeth Allen MS and Janet Spradley MA
Oregon Health & Sciences University, Portland OR, U.S.A.

A2 TREATMENT: GLOBAL

ESTABLISHING A SMOKING CESSATION CLINIC IN A MEDICAL PRACTICE SETTING
Alison McCormick BSc
Eyemouth Medical Practice, Eyemouth, United Kingdom

SMOKING CESSATION CLINICS IN CZECH REPUBLIC: SUCCESSES AND FAILURES
Eva Kralikova and Jirina Radova
Charles University of Prague, First Faculty of Medicine, Prague, Czech Republic

“SMOKING MATTERS” - AN EXAMPLE OF A SMOKING CESSATION SPECIALIST SERVICE IN SCOTLAND - 7 YEARS ON
Trish Grierson BA PG Dip and Sharon Millar MPH PG Dip
Dumfries & Galloway NHS Trust. Dumfries, Scotland, United Kingdom

MINIMAL SMOKING CESSATION INTERVENTION FOR CARDIAC INPATIENTS (C-MIS)
Tessel Y. Kans MA
DEFACTO for smokefree future, The Hague, Netherlands

DO PATIENS WHO STOP SMOKING PRIOR TO SURGERY REMAIN SMOKE-FREE ONE YEAR AFTER SURGERY? (A FOLLOW-UP STUDY ON A RANDOMISED CONTROLLED TRIAL)
Nete Villebro RN, Ann Møller MD and Tom Petersen MD
Bispebejrg University Hospital, Copenhagen, Denmark

EFFICIENCY OF TOBACCO DEPENDENCY TREATMENT IN “HEALTH” SMOKERS AND COPD PATIENS
Marine H Ghambarian, A.M. Kalinina, A.D. Deev PhD
National Centre for Preventive Medicine, Moscow, Russia

TOBACCO USE OUTCOMES AMONG HEAD AND NECK CANCER PATIENTS
Yolanda I. Garces MD, Gary A. Croghan MD,Phd, Ivana T. Croghan PhD, Darrell R. Schroeder MS, Liza M. Nirelli BS, Robert L. Foote MD and Richard D. Hurt MD
Mayo Clinic, Rochester MN, U.S.A.

EVALUATION BTS SMOKING CESSATION GUIDELINES WITH RESPIRATORY PATIENS
Julie S. Kapur BSc, Donna Fitzsimons DPhil, Liam G. Heaney MD, J. Stuart Elborn MD
Belfast City Hospital, N. Ireland

RESULTS OF A PHASE 1, DOUBLE-BLINDED, CONTROLLED SAFETY AND IMMUNOGENICITY TRIAL OF NICVAX”, A CONJUGATED NICOTINE VACCINE
Katalin Lindmayer MD, Gary Horwith MD, Ali Fattom PhD, Robert Naso PhD, Steven Fuller PhD, Larry Muenz PhD, Ann Kennedy MD and Sofiane Ennifar PhD
Nabi Biopharmaceuticals

RESULTS OF OUR SMOKING CESSATION PROGRAM IN YEAR 2000
Salvador Coelho MD, Ligia Flora MD, Carolina Monge MD, Dora Dinis MD and Mª Joâo Valente MD
Serviço de Pneumologia do H.S. Marta e Faculdade de Medicina de Lisboa, Lisboa, Portugal

CONTROLLED TRIAL ON THE EFFECTIVENESS OF A LOW-INTENSITY SMOKING CESSATION INTERVENTION FOR INPATIENTS
Raphaël Bize MD, Rebecca Stoianov RN, Christiane Ruffieux PhD and Jacques Cornuz MD
Institute of Social and Preventive Medicine, Lausanne University, Switzerland

A MULTICOMPONENT CESSATION PROGRAM: COMPARISON BY KIND OF TREATMENT
Francisco Ramos MD, Juan R. Ordoñana PhD, Andrés García MD and Antonio Pérez
Facultad de Psicología, Universidad de Murcia, Spain

TREATMENT CHOICE AND QUIT SUCCESS IN SMOKING CESSATION GROUPS
Kerryn Pammenter BA PhD
Hertfordshire Stop Smoking Service, Welwyn & Hatfield Primary Care Trust, Hertfordshire, United Kingdom

GROUP THERAPY FOR SMOKING CESSATION. CLINICAL AND THERAPEUTIC VARIABLES
Mª Cristina Pinet Ogué MD, Gemma Escuder Romeva PhD, Elisa Ribalta Corona MD and Fátima Larger Brancolini RN
Unidad de Conductas adictivas - Servicio de Psiquiatría. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

MEDICATION TREATMENT OF SUPPORTIVE THERAPY IN SMOKING CESSATION?
Christina Gratziou, N. Rovina, Z. Athanassa, I. Nikoloutsou, K. Francis, E. Evangelou, Z. Sarlani, K. Efthimiou, Th. Kalpakoglou, G. Katsani, A. Roussou, A. Kalanzi and Ch. Roussos
Smoking Cessation Center, Pulmonary and Critical Care Department, Evgenidio Hospital, Medical School, University of Athens, Greece

FAMILIAL PREDICTORS OF SMOKING CESSATION - SMOKING BEHAVIOUR AND SOCIODEMOGRAPHIC FACTORS
Ulla Broms MSc, Jaakko Kaprio MD PhD and Markku Koskenvuo MD PhD
University of Helsinki, Finland

A3 TREATMENT: BUPROPION

PREDICTORS OF SUCCESSFUL OUTCOME DURING ZYBAN®LP TREATMENT IN SMOKERS - PRELIMINARY RESULTS OF A FRENCH MULTICENTRE STUDY
Henri-Jean Aubin MD, François Lebargy MD, Gilbert Lagrue MD, Claude Bidaut-Mazel MD, Joumana Chemali-Hudry MSc, Mannaïg Lecomte PhD and Lidia Poulain PhD
CH Emile Roux, Limeil-Brevannes, France

BUPROPION SR BENEFIT/RISK ANALYSIS
Linda Hyder Ferry MD, J. Andrew Johnston PharmD and Dominy Browning PhD
Innovaa Research, Chapel Hill, U.S.A.

A PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ZYBAN®LP: AN EFFECTIVE AND WELL-TOLERATED AID TO SMOKING CESSATION - PRELIMINARY RESULTS
François Lebargy MD, Henri-Jean Aubin MD, Gilbert Lagrue MD, Claude Bidaut-Mazel MD, Joumana Chemali-Hudry MSc and Lydia Poulain PhD
CH Emile Roux, Limeil-Brevannes, France

ZYBAN: REAL LIFE EFFECTIVENESS IN CLINICAL PRACTICE
Lars Bergmann MD, Dominy Browning PhD, Ingrid Schrijver PhD, Nate Stepner D and Julie Wilson PhD.
GlaxoSmithKline, United Kingdom

BUPROPION AND SMOKING CESSATION IN GENERAL PRACTICE
Michael Murphy FFPHM, Marcus Munafò PhD, Sarah Welch MA, Lesley Jones BA, Robert Walton MD, Mark Dury MRCP, Elaine Johnstone PhD and Patricia Yudkin Dphil
University of Oxford, United Kingdom

ABSTINENCE RATES WITH BUPROPION SR ARE SIMILAR IN MEN AND WOMEN
David Gonzales PhD, Sarah Powell BPharm and Alissa Brown BMedSci MPH
Oregon Health & Sciences University, Portland OR, U.S.A.

BUPROPION SR FOR RELAPSE PREVENTION: A “SLIPS ALLOWED” ANALYSIS
Michael Durcan PhD, J Andrew Johnston PharmD, Jonathan White MS, David Gonzales PhD, David PL Sachs MD, Nancy Rigotti MD and Raymond S. Niaura PhD
GlaxoSmithKline, U.S.A.

PARADOXICAL EFFECT OF BUPROPION ON SMOKING BEHAVIOR, ABOUT TWO CLINICAL CASES
D. Laurence, JM Pinoit, A. Salvé, B. Bonin and A. Gisselmann
Service de Psychiatrie et d’Addictologie, Hôpital Général, Dijon, France

A4 TREATMENT: NRT

NICOTINE DOSE SELECTION USING “TIME TO FIRST CIGARETTE”
Karl Fagerström PhD
Fagerström Consulting, Helsingborg, Sweden

NICOTINE PLASMA LEVELS FOLLOWING COMBINATION TREATMENT WITH NICORETTE® PATCH 15 MG/16H AND NICORETTE® INHALER OR NICORETTE® GUM 2MG
Anna Hansson MSc, Carina Svensson, Thomas Rasmussen MSc and Tor Skärby MD PhD
Pharmacia Consumer Healthcare, Lund, Sweden

INTENSITY OF INITIAL USE OF NICOTINE NASAL SPRAY AND SUCCESS IN SMOKING CESSATION AT 6 MONTHS
Laurent Rey MD, Patrick Bodenmann MD, Françoise Secrétan and Jean-Pierre Zellweger MD
University Medical Policlinic, Lausanne, Switzerland

NICOTINE PATCH AND LOZENGE ARE EFFECTIVE IN HEAVY, DEPENDENT SMOKERS
Saul Shiffman PhD and Michael E. Di Marino MA
Pinney Associates, Pittsburgh, U.S.A.

INCIDENCE AND TREATMENT OF LONG-TERM USE OF NICOTINE REPLACEMENT THERAPY
Fiona Gillison. MSc, Joanne Locker, MSc
Queen’s Mary University of London, England

OVER-THE-COUNTER EFFICACY OF A 15 mg DAYTIME NICOTINE PATCH FOR SMOKING CESSATION: A RANDOMIZED MULTICENTER TRIAL
Barbara Korberly PhD, Gunnar Gustavsson MSc and Elisabeth Kruse PhD
Pharmacia Consumer Heathcare, Bridgewater, U.S.A.

NRT IN RUSSIA: FIRST EVIDENCE-BASED EXPERIENCE
Olga V. Vikhireva MD
State Research Center for Preventive Medicine, Moscow, Russian Federation

NO RISK OF NICOTINE OVERDOSE IN SMOKING CESSATION STUDIES - A RETROSPECTIVE SUMMARY
Elisabeth Kruse PhD, Urbain Säwe MD PhD and Å Westin M Sc
Pharmacia Consumer Healthcare, Helsingborg, Sweden

MATHEMATICAL MODELLING OF NICOTINE REPLACEMENT THERAPIES (NRT): INCREASED RELAPSE RATE AFTER STOPPING TREATMENTS
Jacques Medioni MD, Ivan Berlin MD PhD and Alain Mallet PhD
Clinical Investigations Center, Paris, France

A5 TREATMENT: HARM REDUCTION

CESSATION RATES IN A PLACEBO-CONTROLLED TRIAL OF NICOTINE GUM FOR SMOKING REDUCTION
Poul Wennike MD, Tobias Danielsson BSc, Björn Landfeldt MA, Ake Westin MSc and Philip Tønnesen MD
Dept. of Pulm. Medicine, Gentofte University Hospital, Copenhagen, Denmark
Pharmacia AB, Consumer Healthcare, Helsingborg, Sweden

ETHICAL ISSUES IN TOBACCO HARM REDUCTION RESEARCH
Mark Parascandola PhD
National Cancer Institute, Bethesda, U.S.A.

SMOKING CESSATION AND SMOKING REDUCTION IN ASTHMATICS
Philip Tønnesen MD PhD, Poul Wennike MD, Charlotta Pisinger MD, Fredrik Nilsson MSc and Åke Westin MSc
Dept. of Pulm. Medicine, Gentofte University Hospital, Copenhagen, Denmark
Pharmacia AB, Consumer Healthcare, Helsingborg, Sweden

THE EFFECT OF SHORT-TERM OR LONG-TERM REDUCTION ON SMOKING CESSATION; RESULTS FROM A PLACEBO CONTROLLED SMOKING REDUCTION STUDY WITH THE NICOTINE GUM
Knut-Olaf Haustein MD, Anil Batra MD, Björn Landfeldt MA and Åke Westin M Sc
Inst. Für Nikotinforschung und Raucherentwöhnung Erfurt, Germany

POSTER PRESENTATIONS

Saturday, 5th October
12.30 h – 14.00h

B1 BASIC SCIENCE

NICOTINE-INDUCED TOXICITY IN PRIMARY CULTURES OF RAT CORTICAL CELLS IS MEDIATED BY HIGH AND LOW AFFINITY NICOTINIC RECEPTORS
Yousef Tizabi, Mashael Al-Namaeh and Robert E. Taylor
Department of Pharmacology, College of Medicine, Howard University, Washington DC, U.S.A.

THE TOTAL ANTIOXIDATIVE STATUS AFTER EXPOSURE TO TOBACCO SMOKE IN RATS
Jagna Wrzosek MSc, Ewa Florek PhD, Ewa Ignatowicz PhD and Wojciech Piekoszewski PhD
University of Medical Sciences, Poznan, Poland

A RE-ASSESSMENT OF CYP2A6 AND RISK FOR SMOKING
R.F. Tyndale PhD, E. Hoffmann MSc, B. Xu MD, C. Xu MD PhD, Y.S. Rao MSc, S. Goodz MSc and E.M. Sellers MD PhD
CAMH and Department of Pharmacology, University of Toronto, Toronto, Canada

NOVEL NEUROTENSIN ANALOG BLOCKS NICOTINE-INDUCED LOCOMOTOR SENSITIZATION
Paul Fredrickson MD, Mona Boules PhD, Sally Yerbury and Elliott Richelson MD
Mayo Clinic, Jacksonville, FL, U.S.A.

ACUTE ADMINISTRATION OF BUPROPION INDUCES AN INCREASE OF ATTACK BEHAVIOR IN MICE WITH LOW LEVELS OF AGGRESSIVENESS
Rosa Redolat PhD, M. Carmen Gómez MD, Paloma Vicens PhD and M. Carmen Carrasco PhD
Area de Psicobiología, Facultad de Psicología, Universitat de Valencia, Valencia, Spain

A SYSTEMATIC REVIEW AND META-ANALYSIS OF GENETIC ASSOCIATION STUDIES OF PERSONALITY
Marcus R. Munafò PhD, Robert Walton MD and Jonathan Flint PhD
University of Oxford, United Kingdom

CHARACTERISATION OF GENETIC VARIATION IN THE HUMAN DOPAMINE TRANSPORTER GENE AND ITS RELEVANCE TO SMOKING BEHAVIOUR
Elaine Johnstone PhD, Louisa Draper, Emma York BA, Robyn Jacob BSc, Siân Griffiths BSc, Mike Murphy MSc and Robert Walton MD
Cancer Research UK General Practice Research Group, Oxford, UK

GENETIC FACTORS OF SUSCEPTIBILITY TO TOBACCO SMOKING: MICROSOMAL EPOXI HIDROLASE (EHM) AND RISK OF COPD
C. de la Roza, M. Miravitlles, S. Vilà, B. Lara, R. Jardi, F. Rodríguez-Frías, X. Costa y R. Vidal
Hospital Clinic i Provincial, Servei de Pneumologia, Barcelona, Spain

GENETIC FACTORS OF SUSCEPTIBILITY TO TOBACCO SMOKING: GLUTATHIONE S-TRANSFERASE (GST) AND COPD
C. de la Roza, M. Miravitlles, S. Vilà, B. Lara, R. Jardi, F. Rodríguez-Frías, X. Costa y R. Vidal
Hospital Clinic i Provincial, Servei de Pneumologia, Barcelona, Spain

B2 ADOLESCENTS & INEQUALITIES

SPANISH TEENAGERS AND SMOKING: ASSOCIATED FACTORS
Carlos Cortijo and F. Javier Ayesta
Fac. Medicine, Univ. Cantabria, Santander, Spain

PARENTING PRACTICES AND SMOKING TRANSITIONS IN EARLY ADOLESCENCE
Satu K. Barman, Taru Kinnunen, Lea Pulkkinen, Jaakko Kaprio and Richard J. Rose
Department of Psychology, University of Jyväskylä, Finland

TOBACCO ADS IN FRONT OF PRIMARY AND SECONDARY SCHOOLS DURING 2001 AND 2002 IN THE SPANISH NORTHERN CITY OF SANTANDER
Miriam Otero and F. Javier Ayesta
ECAFRAN & Fac. Medicine, Univ. Cantabria, Santander, Spain

PATTERNS OF EARLY SMOKING ONSET
Elizabeth McMillan-Davey MEd, Jennifer O’Loughlin PhD, Jill Tarasuk MSc, Garbis Meshefedjian MSc and Joseph DiFranza MD
Direction de santé publique de Montréal-Centre, Montreal, Canada

MEASURING NICOTINE DEPENDENCE (ND) IN ADOLESCENTS: QUALITATIVE AND QUANTITATIVE INQUIRY
Jennifer O’Loughlin PhD, Elizabeth McMillan-Davey MEd, Jill Tarasuk MSc, Garbis Meshefedjian MSc and Joseph DiFranza MD
Direction de santé publique de Montréal-Centre, Montreal, Canada

YOUNG PEOPLE’S EXPERIENCE AND EXPECTATION OF SMOKING CESSATION SERVICES
Gill Grimshaw PhD, Alan Stanton FRCPCH, Clare Backburn PhD and Katie Andrews BSc
University of Warwick, Coventry, UK
Wendy Robertson BSc, University of Birmingham, UK

LOW SOCIAL CLASS AND SMOKING CESSATION. RESULTS OF THE INTER99 STUDY
Charlotta Pisinger MD and Torben Jørgensen MD
Centre for Preventive Medicine, University of Copenhagen, Denmark

SMOKING AND INEQUALITIES: ARE CESSATION SERVICES NARROWING THE GAP?
Janet Ferguson MPH, John Chesterman PhD, Ken Judge PhD and Linda Bauld PhD
University of Glasgow, United Kingdom

B3 DIAGNOSIS, WITHDRAWAL & TOXICITY

WHEN IS A NEVER-SMOKER NOT A NEVER-SMOKER? RESULTS FROM THE NONSMOKERS SURVEY
Cynthia S. Pomerleau, PhD, Ovide F. Pomerleau, PhD, Sandy M. Snedecor, MS, Ann M. Mehringer, MS
Nicotine Research Laboratory, Univ. of MI Department of Psychiatry, Ann Arbor, MI, USA

TOBACCO CRAVING QUESTIONNAIRE (TCQ): RELIABILITY AND VALIDITY OF THE FRENCH VERSION
I. Berlin, F. Vorspan, D. Warot, E.G. Singleton, S.J. Heishman.
Dept. of Pharmacology, Pitié-Salpêtrière University Hospital, Paris, France

AUTONOMIC RESPONSE TO TOBACCO-RELATED VISUAL STIMULI
Juan R. Ordoñana PhD, Francisco Ramos MD, Juan P. Sánchez and Jesús Gómez PhD
Facultad de Psicología, Universidad de Murcia, Spain

EFFECTS OF SMOKING EXPOSURE ON SMOKING RELAPSE
Maxine L. Stitzer, Ph.D. and Laura M. Juliano, Ph.D.
Johns Hopkins University School of Medicine, Baltimore, USA

REACTION TO THE SMELL OF OTHER PEOPLE’S CIGARRETTE SMOKE IN RECENT QUITTERS
Joanne Locker MSc and Peter Hajek MA PhD
Barts and The London, Queen Mary’s School of Medicine and Dentristry, London, United Kingdom

CRAVING, WITHDRAWAL SYMPTOMS AND MOOD CHANGES DURING A SHORT PERIOD (3 DAYS) OF CIGARRETTE SMOKING ABSTINENCE
Vincenzo Teneggi, Lisa Squassante, Stefano Milleri, Luigi Ziviani, Laura Iavarone and Alan Bye
GlaxoSmithKline SpA, Medicine Research Centre, Verona, Italy

INCREASE IN COMMON COLD SYMPTOMS AND MOUTH ULCERS FOLLOWING SMOKING CESSATION
Michael Ussher PhD, Robert West PhD, Andrew Steptoe PhD and Andy McEwen MSc
St. George’s Hospital Medical School, University College London, London, United Kingdom

EFFECTS OF THE NICOTINE PATCH AND A 5HT3 ANTAGONIST ON TOBACCO WITHDRAWAL SYMPTOMS
Dorothy Hatsukami PhD, Marc Mooney MA and Joni Jensen MPH
University of Minnesota, Minneapolis, U.S.A.

ASSOCIATION BETWEEN SMOKING AND CARDIOVASCULAR RISK FACTORS IN YOUNG ADULTS
Luis Sainz de Rozas Md, Alberto Ferrero Md, Eduardo Predejón Md, Jesús García-Cobo Md, Maite García-Unzueta Md, Javier Llorca Prof. and José R. Berrazueta Prof.
Cardiology Unit, Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain

EFFECT OF SMOKING ON ENDOTHELIUM-DEPENDENT ARTERIAL VASODILATION IN HEALTHY YOUNG ADULTS
Luis Sainz de Rozas Md, Alberto Ferrero Md, Eduardo Predejón Md, Jesús García-Cobo Md, Inmaculada de Mier Md, José Gutiérrez Md and José R. Berrazueta Prof.
Cardiology Unit, Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain

PERINATAL TOBACCO USE AND MATERNAL/INFANT OUTCOMES IN PREGNANT DRUG DEPENDENT WOMEN
D. Svikis, S. Lanni, L. Jansson, D. Miles, D. Raiford and R. Pickens
Virginia Commonwealth University, Richmond, VA, U.S.A.
Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

PERSONAL TOBACCO CONSUMPTION AND HEALTH RELATED QUALITY OF LIFE IN SEVERE COPD PATIENTS
J.E. Alonso, M.B. Gallego, S. Carrizo, J.M. Marín.
Tobacco Unit Respiratory Service. Hospital Miguel Servet. Zaragoza.Spain

B4 DEPRESSION, GENDER & DRUG ABUSE

NICOTINE BIASES EYE-GAZE AWAY FROM NEGATIVE AND TOWARD POSITIVE PICTURES: IMPLICATIONS FOR AFFECT REGULATION
David G. Gilbert PhD, Adam Izetelny MA, Heather Heaslett BA, Amy Skerly BA and Norka E. Rabinovich BA
Southern Illinois University, Carbondale IL, U.S.A.

DOPAMINERGIC ACTIVITY IN DEPRESSED SMOKERS, A PET STUDY
Laura Cardenas MD, Shitij Kapur MD, Sylvain Houle MD, Claudio A. Naranjo MD, Helen Mayberg MD and Usoa E. Busto PharmD
Centre for Addiction and Mental Health, University of Toronto, Canada

HEROIN-DEPENDENT TOBACCO SMOKERS: RELATIONSHIPS BETWEEN SMOKING BEHAVIOR, PSYCHIATRIC SYMPTOMS AND COTININE LEVELS
Fernando Martín and F. Javier Ayesta
Fac. Medicine, Univ. Cantabria, Santander, Spain

COMPARISON OF SMOKING BEHAVIOUR IN DEPRESSED & NON-DEPRESSED SMOKERS: A TOPOGRAPHICAL ANALYSIS
Debra Malpass BSc and Suzanne Higgs PhD
University of Birmingham, Birmingham, United Kingdom

RELIABILITY AND VALIDITY OF A NICOTINE ADDICTION SCALE
Aurora Tapia-Díaz MSc, Noé Alvarado-Vásquez MSc, José Luis Arreola-Ramírez VMD, María García-López MD and José Pérez-Neria PhD
National Institute of Respiratory Diseases, México

WHAT HAPPENS TO RATINGS OF DEPRESSION WHEN DEPRESSED SMOKERS QUIT?
Hayden McRobbie MB, ChB, Raluca Mihaescu MD and Peter Hajek PhD
Barts and The London, Queen Mary’s School of Medicine and Dentristry, London, United Kingdom

DEPRESSION DISORDERS AND ANXIETY PREVALENCE IN SMOKING PATIENTS ACCORDING TO GENDER
Felisa Domínguez Grandal, Mercedes Fraga Díez and Joaquina Campo Cascón
Centro de Salud de Vigo-Centro, Sergas, Galicia, Spain

SMOKING AND GENDER DIFFERENCES
I. Nerín, A. Crucelaegui and A. Mas
Unit of Tabaquism. Dept. of Medicine and Psichiatry. University of Zaragoza, Spain

GENDER DIFFERENCES IN A SMOKING CESSATION PROGRAM IN A HEALTH CARE SERVICE
Manuel Rosas PhD and José A. Silva MD
Hospital Pedro Hispano, Matosinhos, Portugal

BODY WEIGHT CONCERNS: INFLUENCE ON THE SMOKING BEHAVIOR OF SPANISH ADOLESCENTS
Laura de la Rosa, Miriam Otero, Carlos Cortijo and F. Javier Ayesta
Fac. Medicine, Univ. Cantabria, Santander, Spain

IMPULSIVITY IN SMOKING, NON-SMOKING, AND EX-SMOKING ALCOHOLICS
Marilyn D. Skinner MA, Henri-Jean Aubin MD and Ivan Berlin MD
Hospital Emile Roux, Limeil-Brévannes, France

TOBACCO USE DURING OPIOID DETOXIFICATION
B.M. Tripathi MD, Hemraj Pal MD and Sanjay K. Agrawal MD
All India Institute of Medical Sciences, New Delhi, India

SMOKING AND PSYCHIATRIC SYMPTOMS IN SPANISH ADOLESCENTS
F. Javier Ayesta and Carlos Cortijo
Fac. Medicine, Univ. Cantabria, Santander, Spain

B5 PHYSICIANS AND SMOKING

TOBACCO CONSUMPTION AND MOTIVATION STAGE TO STOP SMOKING IN HEALTH PROFESSIONALS
Manuel Rosas PhD and Filipa Baptista PhD
Hospital Pedro Hispano Matosinhos, Portugal

PHYSICIANS AND SMOKING IN SPAIN: ARE DOCTORS SETTING THEIR OWN HOUSE IN ORDER?
Esteve Saltó MD, Mireia Jané MD, Helios Pardell PhD, Esteve Fernández PhD, Ricard Tresserras PhD, Josep L. Taberner MD and Lluís Salleras PhD
Department of Health and Social Security. Autonomous Government of Catalonia, Barcelona, Spain

MEDICAL STUDENTS AND SMOKING
Petr Nesnidal, Eva Kralikova
Medical Faculty, Charles University, Prague, Czech Republic

A REPORT ABOUT SMOKING AMONG STUDENTS OF A SELECTIVE PRAGUE HIGH SCHOOL
Jana Knizkova, Eva Kralikova
Institute of Hygiene and Epidemiology, Faculty of Medicine, Charles University, Prague, Czech Republic

SMOKING, PREVENTIVE CARDIOLOGY AND HIGH SCHOOL STUDENTS
Lenka Bosanka, Eva Kralikova
Institute of Hygiene and Epidemiology, Faculty of Medicine, Charles University, Prague, Czech Republic

FAMILY PHYICIANS AND TOBACCO: “SMOKE-FREE WEEK”
L. Clemente, A. Solbes, J. Amador, L. Aguilera, F. Dominguez, M. Torrecilla
Grupo de Abordaje del Tabaquismo de SEMFYC. Salamanca. Spain

ANTI-TOBACCO MEDICAL ADVICE: UTILIZATION AND DIFFERENCIAL STUDY BETWEEN PNEUMOLOGY vs. PRIMARY CARE
J.A. Riesco, A. Marcos, J. Corral, M.J. Lavilla, J. Sánchez de Cos, M.A. Sojo, C. Disdier and J.F. Masa
Pneumology Department, Hospital San Pedro de Alcantara, Cáceres, Spain

DIFFERENCIAL STUDY OF THE UTILIZATION OF ANTI-TOBACCO ADVICE: ENT vs. PRIMARY CARE
M.J. Lavilla, J.A. Riesco, M. García, A. Marcos, J.L. Sánchez-Jara, F. Benítez, J. Marcos and B. García
Pneumology Department, Hospital San Pedro de Alcantara, Cáceres, Spain

SMOKING CESSATION METHODS OF GENERAL PRACTITIONERS IN FINLAND 2001
Noël C. Barengo MD, H. Patrick Sandström, Vesa J. Jormanainen MD Phd and Markku T. Myllykangas PhD
National Public Health Institute, Finland

GENERAL PRACTITIONERS’ VIEWS ON THE PROVISION OF NICOTINE REPLACEMENT THERAPY AND BUPROPION
Andy McEwen MSc, BA and Robert West PhD, BSc
St. George’s Hospital Medical School, London, U.K.

TOBACCO INTERVENTION SKILLS OF PEDIATRICIANS
C. Keith Haddock PhD, Norman Hymowitz PhD, Joseph Schwab MD, Kristin K. O’Byrne and Risa J. Stein PhD
University of Missouri, Kansas, U.S.A.

EFFECTIVE METHODS TO ENGAGE DOCTORS IN PROVIDING TREATMENT FOR TOBACCO DEPENDENCE
Eva Jane Llopis, Peter Anderson
Prevention Research Centre, Nijmegen University, Netherlands
Department of Primary Care, Oxford University, England

SMOKING CESSATION TRAINING FOR POST GRADUATE GPS IN THE UK - A PILOT PROGRAMME
Lisa Buck BA, Sinead Jones PhD
BMA Tobacco Control Resource Centre